Computational Assessment of Substituted 2-Mercaptobenzimidazole Schiff Bases Derivatives Targeting α-Amylase, α-Glucosidase, and PPAR-γ Receptor in Type 2 Diabetes Mellitus
Computational docking reveals promising multi-target Schiff bases for reducing postprandial glucose in type 2 diabetes, indicating their potential as antidiabetic agents.
Key Points
The study examines substituted 2-mercaptobenzimidazole Schiff bases targeting α-amylase and α-glucosidase in type 2 diabetes.
Molecular docking identified several compounds with stronger binding energies than the reference drug acarbose.
Key interactions involved hydrogen bonds and hydrophobic contacts with important amino acids of the target enzymes.
These findings support the potential of Schiff bases as multi-target agents for new antidiabetic therapies.